Unlocking the Secrets of Complex Dry Eye Cases: A Deep Dive into Modern Management
Dry eye disease and ocular surface disorders are becoming increasingly prevalent, especially among aging populations with various health issues. But what happens when these conditions become stubbornly resistant to treatment? Ophthalmologists are now grappling with this very challenge, seeking innovative solutions for the most complex cases.
In this insightful Q&A, we delve into the minds of leading ophthalmologists, Dr. Christopher E. Starr and Dr. William Trattler, as they share their expertise on managing refractory dry eye patients with systemic health complications. They discuss the evolving landscape of diagnostic tools, emerging therapies, and practical strategies for tackling these intricate cases.
Dr. Starr boldly asserts that there's no such thing as an untreatable dry eye condition. He believes that with thorough investigation and the right combination of treatments, all dry eye and ocular surface diseases can be managed. However, he acknowledges that the presence of systemic conditions, such as autoimmune diseases, can complicate matters and require simultaneous management. Interestingly, Dr. Starr suggests that what is often labeled as 'refractory dry eye' may actually be a misdiagnosis, with neuropathic corneal pain syndrome being a more accurate diagnosis in many cases.
Dr. Trattler offers a practical approach for severe dry eye cases, emphasizing the importance of starting with the basics. He recommends beginning with therapies to increase tear volume, followed by anti-inflammatory medications, and then focusing on the eyelids to improve the tear film's lipid layer. Dr. Trattler also highlights the potential of a new topical therapy, acoltremon, which stimulates basal tear secretion. For the most challenging cases, he suggests advanced therapies like serum tears and amniotic membranes.
When it comes to emerging therapies, both doctors are optimistic. Dr. Starr is particularly excited about novel compounds with unique mechanisms, such as acoltremon and perfluorohexyloctane, which have recently been approved. He also eagerly awaits the approval of two other medications for meibomian gland dysfunction and reproxolap. Interestingly, Dr. Starr considers autologous serum drops as the ultimate biologic therapy, and he's delighted that Ocubio is making high-quality, non-refrigerated drops accessible to patients.
Diagnostic technology has significantly enhanced treatment personalization, according to Dr. Starr. He highlights the importance of osmolarity and MMP-9 testing, along with meibography, in his dry eye workup. While he still wishes for noninvasive tear break-up time (TBUT) and lactoferrin/IgE testing, he's thrilled with the Brill noncontact esthesiometer, which has improved his diagnostic accuracy for neuropathic ocular pain and neurotrophic keratitis.
Looking to the future, what innovations are on the horizon? Dr. Starr isn't aware of any imminent breakthroughs in tear film imaging or diagnostic tests, but the field is ever-evolving.
This Q&A offers a glimpse into the cutting-edge strategies and technologies that are shaping the management of complex dry eye and ocular surface cases. It highlights the importance of a comprehensive approach, considering both ocular and systemic factors, and the promise of emerging therapies and diagnostic tools. But the question remains: are there truly untreatable dry eye cases, or is it a matter of finding the right combination of treatments and diagnoses?
Note: This transcript has been edited for clarity and length.
